Immunohistochemical prognostic factors of primary refractory Hodgkin’s lymphoma
Vol. 60 No. 5 (2014), Articles
Vol. 60 No. 5 (2014)

Immunohistochemical prognostic factors of primary refractory Hodgkin’s lymphoma

Articles
https://doi.org/10.37469/0507-3758-2014-60-5-625-629
Published 15.12.2014
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
N.N. Petrov Research Institute of Oncology
PDF (Русский)

Keywords

Hodgkin’s lymphoma
immunohistochemical markers
prognostic factors
primary refractory form

How to Cite

, , , , , & . (2014). Immunohistochemical prognostic factors of primary refractory Hodgkin’s lymphoma. Voprosy Onkologii, 60(5), 625–629. https://doi.org/10.37469/0507-3758-2014-60-5-625-629
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

In order to identify immunohistochemical markers associated with primary refractory Hodgkin’s lymphoma, 20 patients with primary refractory form at stage IIAB in complete remission underwent histological examination and immunohistochemical determination of Bcl-6, Bcl-2, с -kit (CD117), CD15, CD30, P-53, Ki-67. In the group with primary refractory Hodgkin’s lymphoma at stage IIAB Bcl-6 expression was found in 2 patients (10%), Bcl-2 in 14 patients (70%), c-kit (CD117) in 16 patients (80%), CD15 in 9 patients (45%). The expression of CD30 and P-53 was observed in all patients in this group (100%). The expression of Ki-67 ranged from 20% to 100%, 80-100% in 16 patients (80%). As a result, multivariate analysis revealed no immunohistochemical markers of primary refractory Hodgkin’s lymphoma. In univariate and multivariate analyzes in a group of primary refractory Hodgkin’s lymphoma a high level P-53 expression (80-100%) was significantly associated with decreased overall survival. A 5-year overall survival in patients with Hodgkin’s lymphoma with the expression level of P-53 <80% was 78%, with the expression level of P-53 80-100%-22%. A 5-year overall survival of Hodgkin’s lymphoma primary patients in complete remission significantly exceeded the rates of patients with primary refractory Hodgkin’s lymphoma-100% vs. 52%.
https://doi.org/10.37469/0507-3758-2014-60-5-625-629
PDF (Русский)

References

Ковригина А.М. Морфологическая и иммуногистохимическая дифференциальная диагностика лимфомы Ходжкина и крупноклеточных лимфом // Автореф. дис.. канд. мед. наук. - М. - 2006. - 50 с.

Antic D., Tomin D., Cemerikic V., Boskovic D. The correlation between the immunostains for P53, Ki67, PRB, BCL-6, EBV-LMP expression and classical prognostic factors in Hodgkin lymphoma // Haematologica. - 2007. - Vol. 92 (s5). - P. 46 (Abstr. P045).

Axdorph U., Sjoberg J., Grimfors G. et al. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin’s disease // Ann. Oncol. - 2000. - Vol. 11. - P. 1405-1411.

Bargonetti J., Manfredi J.J. Multiple roles of the tumor suppressor p53 // Curr. Opin. Oncol. - 2002. - Vol. 14 - № 1. - P. 86-91.

Bartlett N.L., Forero-Torres A., Rosenblatt J. et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) // J. Clin. Oncol. - 2009. - Vol. 27. - P. 15s (Abstr. 8500).

Canioni D., Deau-Fischer B., Taupin P. et al. Prognostic Significance of new immunohistochemical marcers in Refractory classical Hodgkin lymphoma: a study of 59 cases // PLoS ONE. - 2009. Vol. 4. - № 7. - P. e6341.

Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic enaluations in human malignancies // Semin Cancer Biol. - 1990. - Vol. 1. - № 3. - P. 99-206.

Gerdes J., Schwab U., Lemke H. Stein Producing of a mouse monoclonal antibody reactive with a human nuclear antigen associated witn cell proliferation // Int. J. Cancer. - 1983. - Vol. 31. - № 1. - P. 13-20.

Mendler J.H., Friedberg J.W. Salvage therapy in Hodgkin’s lymphoma // Oncologist. - 2009. - Vol. 14. - № 4. - P. 425-432.

Molin D., Edstrom A., Glimelius I. et al. Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma // Br. J. Hematol. - 2002. - Vol. 119. - P. 122-124.

Nieder C., Petersen S., Petersen C., Thames H.D. The challenge of p53 as prognostic and predictive factor in Hodgkin’s or non- Hodgkin’s lymphoma // Ann. Hematol. - 2001. - Vol. 80. - P. 2-8.

Rassidakis G.Z., Medeiros L.J., Vassilakopoulos T.P. et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens // Blood. - 2002. - Vol. 100. - P. 3935-3941.

Sarris A.H., Kliche K.O., Nadali G. Biologic factors in Hodgkin’s disease: a window into prognosis and a guide for investigational therapy // Leuk. Lymphoma. - 2001. - Vol. 42 (suppl. 2). - P. 10.

Smolewski P., Niewiadomska H., Los E., Robak T. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin’s disease // Int. J. Oncol. - 2000. - Vol. 17. - P. 603-609.

van Sprosen D.J., Peh S.C., Vrints L.W. et al. Clinical drug-resistant nodular sclerosing Hodgkin’s lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells // Histopathology. - 2000. - Vol. 37. - № 5. - Р. 420-426.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...